QRG Capital Management Inc. Trims Stock Position in Edwards Lifesciences Corporation $EW

QRG Capital Management Inc. trimmed its holdings in Edwards Lifesciences Corporation (NYSE:EW) by 51.7% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 40,238 shares of the medical research company’s stock after selling 43,056 shares during the quarter. QRG Capital Management Inc.’s holdings in Edwards Lifesciences were worth $3,147,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Quantbot Technologies LP purchased a new position in Edwards Lifesciences during the first quarter valued at approximately $26,000. SouthState Corp acquired a new stake in shares of Edwards Lifesciences during the 1st quarter worth approximately $27,000. Global X Japan Co. Ltd. grew its stake in shares of Edwards Lifesciences by 116.1% during the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company’s stock worth $29,000 after purchasing an additional 216 shares during the period. Tradewinds Capital Management LLC increased its holdings in shares of Edwards Lifesciences by 102.5% during the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 205 shares in the last quarter. Finally, Rossby Financial LCC acquired a new position in shares of Edwards Lifesciences in the 1st quarter valued at $29,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Performance

NYSE EW opened at $76.59 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The stock’s 50 day simple moving average is $78.46 and its 200-day simple moving average is $76.05. The company has a market cap of $44.97 billion, a PE ratio of 11.02, a price-to-earnings-growth ratio of 3.71 and a beta of 1.05. Edwards Lifesciences Corporation has a 1-year low of $64.00 and a 1-year high of $83.00.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.62 by $0.05. The firm had revenue of $1.53 billion during the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the previous year, the business earned $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on EW. Deutsche Bank Aktiengesellschaft raised their price target on shares of Edwards Lifesciences from $85.00 to $94.00 and gave the company a “buy” rating in a research report on Friday, July 25th. Canaccord Genuity Group lifted their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the company a “hold” rating in a research note on Friday, July 25th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Edwards Lifesciences in a report on Saturday, September 27th. Truist Financial raised their price objective on Edwards Lifesciences from $81.00 to $82.00 and gave the company a “hold” rating in a report on Friday, July 25th. Finally, Morgan Stanley increased their target price on Edwards Lifesciences from $75.00 to $81.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 15th. Three analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $86.61.

Insider Transactions at Edwards Lifesciences

In related news, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This represents a 4.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.